Skip to Content
  • Revenues ($M)
    $6,149
  • Revenue Percent Change
    -
  • Profits ($M)
    $956
  • Profits Percent Change
    -
  • Assets ($M)
    $12,329
  • Employees
    17,000
  • Market Value — as of March 31, 2016 ($M)
    $27,522
  • Previous Rank
    -
  • Morning Consult Brand Index
    D-

Baxalta, a biopharmeceutical company that specializes in treating rare conditions, was spun off from the healthcare giant Baxter International (ranked No. 286 on this year’s Forutne 500) last July. Earning $6.1 billion in revenue its inaugural year, the young company is looking forward to greater growth as it awaits the conclusion of a $32 billion merger with Shire.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Ludwig N. Hantson
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Bannockburn, IL
Websitehttp://www.baxalta.com
Years on Fortune 500 List1
Employees17,000
Spun off from Baxter International (2015 rank: 286), July 1, 2015. Acquired by Shire (Ireland), June 3, 2016.

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$6,149-
Profits ($M)$956-
Assets ($M)$12,329-
Total Stockholder Equity ($M)$3,924-
Market Value — as of March 31, 2016 ($M)$27,522-

Profit Ratios

Profit as % of Revenues15.5%
Profits as % of Assets7.8%
Profits as % of Stockholder Equity24.4%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.4
EPS % Change (from 2014)-
EPS % Change (5 year annual rate)-
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2015)-
Total Return to Investors (5 year, annualized)-
Total Return to Investors (10 year, annualized)-